Blood
Articles in this Issue
Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization
Abstract Introduction Recent evidence showing benefit of blinatumomab (blina), a CD19xCD3, in upfront treatment of B-cell acute lymphocytic...
Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.
Abstract INTRODUCTION High-dose melphalan remains the standard conditioning regimen for autologous hematopoietic stem cell transplantation (A...
Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition with sprycel startup study
Abstract Introduction Frontline treatment of chronic phase chronic myeloid leukemia (CP-CML) with the second-generation tyrosine kinase inhi...
Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study
Abstract Background: Mosunetuzumab, a CD20xCD3 bispecific antibody, can be administered in the outpatient setting for a fixed duration. Mosu...
CD49d expression is epigenetically regulated in chronic lymphocytic leukemia: Insights from CD49d bimodal cases
Abstract CD49d (integrin α4) is a key adhesion molecule in chronic lymphocytic leukemia (CLL) with prognostic relevance. While most cases sh...
Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis
Abstract Background Diffuse large B-cell lymphoma (DLBCL) complicated with hemophagocytic lymphohistiocytosis (HLH) repr...
Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study
Abstract Introduction. IMIDs occur in about 15% of MDS and CMML (Mekinian et al, Rheumatology (2016;55:291-300), but the precise relationshi...
Characterization of multiple myeloma genomes with LinkPrep™ assay enables sensitive detection of somatic variation and SV-driven interactions of the 3D genome.
Abstract Introduction: Multiple myeloma (MM) is characterized by its genomic complexity that includes recurrent driver s...
Identification of novel predictors of cardiovascular disease risk in MDS patients: Results of a prospective observational single-centre cohort study
Abstract Α shared pathobiology between MDS and cardiovascular disease(CVD) is postulated, but many MDS patients do not develop CVD and only...
Transfusion burden across hematologic and solid tumors: A real-world comparative study in AML, multiple myeloma, lung cancer, and melanoma
Abstract Transfusions are a routine aspect of cancer care; however, their frequency and implications vary by tumor type and treatment. We hy...
Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)
Abstract Background: Obe-cel is an autologous fast off-rate 4-1BB-ζ CD19-directed CAR T-cell therapy with demonstrated clinical efficacy in...
Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia
Abstract Introduction The combination of hypomethylating agent (HMA) and 28 days of venetoclax (VEN) is a standard first...
Causes of death in young children with sickle cell disease and sickle trait in young children investigated by the child health and mortality prevention surveillance (CHAMPS) network
Abstract Background: In sub-Saharan Africa as much as 60% of children with sickle cell disease (SCD) die before the age of five. Despite hig...
Single-cell transcriptional profiling identifies ADGRG1+ CD8 T cells as critical mediators of graft-versus-leukemia effect in AML relapse after haploidentical hematopoietic stem cell transplantation
Abstract Purpose: Relapse remains a major obstacle in acute myeloid leukemia (AML) patients after haploidentical hematopoietic stem cell tra...
Comparison of hemostatic dosing of factor IX wild-type and padua (R338L) in multiple hemophilia B mouse models
Abstract Introduction The hyperactive factor IX (FIX) variant Padua (R338L) has turbocharged gene therapy for hemophilia B (HB). FIX-Padua i...
Germline predisposition in hematologic malignancies: A study of 22 cases with germline DNA
Abstract Introduction: About 7–15% of patients with leukemia or myelodysplastic syndromes (MDS) may harbor germline mutations, even in the a...
A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia
Abstract Introduction: Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder, and allogeneic hematopoietic stem ce...
Outcomes with a combination of treosulfan and fludarabine in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
Abstract Introduction: Conventionally, myeloablation with high-dose chemotherapy, with or without total body irradiation (TBI), has been use...
Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation
Abstract Introduction Measurable residual disease (MRD) monitoring is informative for long-term prognosis in patients with acute myeloid leu...
Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib (PAC): Results from the my-PAC study
Abstract Background Pacritinib (PAC), a JAK1-sparing JAK2/IRAK1/ACVR1 inhibitor approved for patients (pts) with myelofi...
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results
Abstract Introduction Approximately 40% of patients with DLBCL will experience relapse after initial treatment with stan...
The role of palliative care in sickle cell disease: A single database literature review of contemporary outcomes data
Abstract Introduction: Patients with sickle cell disease (SCD) have been shown to have significantly reduced life expectancy relative to the...
Stimulated CAR-T cells from non-Hodgkin lymphomas patients engage and activate monocytes via extracellular vesicles
Abstract Chimeric Antigen Receptor-T (CAR-T) cell therapy have changed the treatment paradigms in several hematological malignancies, especi...
Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms
Abstract Introduction Acquired von Willebrand syndrome (AvWS) is a rare condition that results in biological alterations of primary hemostas...
Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia
Abstract High-throughput sequencing (HTS) of clonal immunoglobulin (Ig) gene rearrangements has become a mainstay of B-lymphoblastic leukemi...